Yüklüyor......
Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma
BACKGROUND: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, in combination with the programmed cell death-1 (PD-1) antagonist pembrolizumab. METHODS: The study was divided into two parts; parts A...
Kaydedildi:
| Yayımlandı: | J Immunother Cancer |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMJ Publishing Group
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7682474/ https://ncbi.nlm.nih.gov/pubmed/33219094 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001681 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|